bleeding occurs less frequently than expected. Molho et al 1 showed that 9% of the young adult patients with severe hemophilia did not bleed into joints. The exact mechanism underlying this variability in bleeding pattern is not completely understood. Several mechanisms have been proposed to explain this discrepancy, including coinheritance of some prothrombotic genetic mutations, impaired fibrinolysis, and elevated endogenous thrombin generation. [2] [3] [4] Of those, the prothrombotic mutations have drawn much attention. Factor V Leiden (FVL) and the factor II mutations are two of the most frequent genetic risk factors leading to venous thrombosis by causing activated protein C resistance and increased levels of plasma prothrombin, respectively. A number of studies on severe hemophiliacs showed that coinheritance of these prothrombotic factors H emophilia A and B are X-linked bleeding disorders characterized by deficiencies of factor VIII and factor IX, respectively. The factor activity usually correlates well with the clinical severity of the disease, leading to 3 clinical forms largely defined as severe (factor activity < 1%), moderate (factor activity 1%-5%) and mild (factor activity 6%-50%) hemophilia. In a subset of severe hemophilic patients, About 10% of patients with severe hemophilia exhibit a milder clinical phenotype with less frequent bleeds. Among many other factors, coinheritance of prothrombotic mutations have been proposed to act as modulators of clinical severity in severe hemophilia. We conducted a study to evaluate the impact of 3 prothrombotic mutations (factor V Leiden, factor II, and methylenetetrahydrofolate reductase mutations) on clinical phenotype of patients with severe hemophilia in our institution. For this purpose we compared the average annual factor concentrate consumption between carriers and noncarriers of prothrombotic mutations. A total of 38 hemophilia A and B patients with factor levels less than 1 were recruited between October 2006 and October 2007. Prothrombotic mutations were detected in venous blood using polymerase chain reaction amplification technique. Eighteen patients (47%) carried no prothrombotic mutations. The remaining 20 patients (53%) were found to be carriers of either 1 or 2 mutations. Median age in both carrier and the noncarrier groups was 27 years. None of the patients in either group gave a history of thromboembolic event. Median annual factor concentrate consumptions in carriers and noncarriers were 610 ± 530 units/kg and 770 ± 670 units/kg, respectively (P = .203). Our results demonstrated no significant difference in annual factor concentrate consumption between carriers and noncarriers of prothrombotic mutations. Considering that average annual factor consumption is a surrogate indicator of clinical phenotype, we concluded that coinheritance of prothrombotic mutations was not associated with occurrence of different clinical phenotypes in severe hemophilia.
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Keywords: hemophilia; prothrombotic mutations; factor consumption was related to a milder clinical phenotype. 5, 6 Other studies however, could not demonstrate this beneficial protective effect. 7 Thus, precise contribution of prothrombotic risk factors in modulating clinical phenotype of severe hemophilia is not yet well established.
In the present study we aimed to evaluate the impact of prothrombotic mutations, that is, FVL (G1691A), factor II mutation (G20210A), and methylenetetrahydrofolate reductase (MTHFR) C677T variant, on clinical phenotype of adult patients with severe hemophilia. For this purpose we compared the average annual factor concentrate consumption between carriers and noncarriers of prothrombotic mutations.
Materials and Methods

Study Population
Adult patients (age >16 years) with severe hemophilia (factor VIII or IX < 1%) who are followed at the outpatient clinics of the Haematology Department of Cerrahpasa Medical Faculty, Istanbul University, were included in the study. Patients with inhibitors and patients receiving secondary or intermittent prophylaxis were not included. All participating patients gave written consent, and the protocol was approved by the local ethics committee.
In Turkey, patients are generally treated "on demand," and prophylaxis has not been a routine procedure for severe hemophiliacs until recent years. Currently, health care systems in our country reimburse prophylactic factor replacement therapy only for severe hemophilic children and selected adult patients with frequent bleedings. Thus, almost all of our adult hemophiliacs receive on-demand factor-replacement therapy, and most of them suffer from frequent hemorrhages, or advanced stage hemophilic arthropathy and its related complications.
Study Design
Patients with known severe hemophilia were consecutively recruited between October 2006 and October 2007 when they were admitted to hematology outpatient clinics following a hemorrhage. Blood samples were taken and stored appropriately until laboratory testing. Patients' medical records and factor prescription booklets were retrospectively reviewed to obtain data on clinical and laboratory characteristics of the patients as well as on their factor utilization. The total factor usage of the last 24 months was considered for each patient when the average annual factor consumption per kilogram of body weight was calculated. Factors used for elective interventional and surgical procedures were not taken into account.
Since 2002 it is obligatory for all hemophilic patients in Turkey to carry special factor prescription booklets delivered by the Ministry of Health. These booklets include general information on the patient's medical characteristics such as diagnosis, level of factor activity, inhibitor status, etc, as well as pages for factor prescription. Each time a patient bleeds, he must be examined by his physician. Patients cannot get their factor concentrates unless their physicians write into the prescription booklet the site of bleeding, target factor level, and the necessary amount of factor concentrate needed. Despite its limitations, this system provides accurate data on the extent and frequency of factor usage.
Blood Sampling and Laboratory Analysis
Two milliliters of venous blood was obtained in ethylene diamine tetra-acetic acid (EDTA)-containing sample tubes (Greiner Bio-One GmBH, Kremsmünster, Austria) from patients by peripheral venipuncture when they came to the outpatient clinic due to bleeding. Using standard techniques as previously described, DNA was extracted from blood samples and stored at -70°C. 8 Polymerase chain reaction (PCR) amplification for the detection of FVL, factor II, and MTHFR mutations and visualization of the PCR products were carried out using a commercial assay (CVD StripASSAY, Vienna Lab, Vienna, Austria).
Statistical Analysis
All descriptive and comparative statistical analyses were carried out using SPSS v.11 for Windows (SPSS Inc, Chicago, Ill). The groups were not normally distributed; therefore, we used the nonparametric Mann-Whitney U test to compare factor consumption values between prothrombotic mutation carriers and noncarriers. A P value < .05 was considered statistically significant.
Results
Patient characteristics are summarized in Tables 1  and 2 . Thirty-eight severe hemophilic patients were recruited during the study period. Of those, 18 (47%) patients carried none of the tested prothrombotic mutations. The remaining 20 patients (53%) were carriers of either 1 or 2 mutations. Factor V Leiden, factor II, and MTHFR mutations were detected in 5 (13%), 6 (15%), and 14 (36%) of the patients, respectively. Five patients showed coinheritance of more than 1 prothrombotic mutation. Three of them were heterozygous for factor II and MTHFR, and the other 2 were heterozygous for FVL and MTHFR mutations. Only 1 patient had a homozygous MTHFR mutation.
Median age in both carrier and noncarrier groups was 27 years (range for carriers, 21-49; range for noncarriers, 16-48 years). Median age of diagnosis in the carrier group (35 months; range, 3-120 months) was not significantly different from that of the noncarriers (36 months; range, 1-216 months). None of the patients in either group gave a history of thromboembolic event.
Median annual factor concentrate consumptions in the carriers and noncarriers were 610 ± 530 units/kg and 770 ± 670 units/kg, respectively. The difference between both groups with respect to annual factor consumption did not reach statistical significance (P = .203).
Discussion
The severity and frequency of bleeding and, consequently, factor consumption in hemophilia have been associated with a number of genetic and environmental factors such as presence of inhibitors, type of factor gene mutation, age of the patient, and intensity of physical activity. 9, 10 In the last decade, a couple of reports have been published investigating the significance of coinheritance of prothrombotic genetic mutations in modulating the bleeding phenotype of hemophilic patients. There are some in vitro and in vivo studies that demonstrated a potential beneficial effect of a coexisting prothrombotic mutation in terms of bleeding outcome. 11, 12 Shortly after the discovery of FVL mutation in 1994, Nichols et al 13 Although it is generally accepted that there are 2 clinically different disease phenotypes (mild and severe) in severe hemophilia, well-defined criteria to distinguish mild from severe phenotype are still lacking. For countries where prophylaxis is routinely performed, age at first joint bleeding may be a useful indicator of disease severity. However, other parameters should be considered for evaluating clinical severity of hemophilia in countries like Turkey, where patients are generally treated on demand. In that aspect, bleeding frequency, the extent of hemophilic arthropathy, or factor utilization can be used as determinants of severity in hemophilia. In our study we used average annual factor concentrate consumption as a surrogate marker for clinical severity.
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of FVL, factor II, and MTHFR mutations in severe hemophilic adults. Considering that average annual factor consumption is a surrogate indicator of clinical phenotype, one can conclude that the distribution of the above-mentioned prothrombotic mutations was not associated with occurrence of different clinical phenotypes in severe hemophilia. Our finding partly supported the results of other earlier studies. However, it is very difficult to compare related studies in the literature and draw clear-cut conclusions, as each study evaluated different combinations of thrombophilic factors in different subsets of patients.
As a subgroup analysis we also evaluated the annual factor consumption of patients carrying more than 1 prothrombotic mutation. The median factor utilization of those 5 patients was found to be 310 units/kg/year, which was far below the median factor consumption values of both groups. Because the number of the patients in this category was low, no statistical analysis was carried out. It has been stated that heterozygosity for MTHFR was not associated with elevated risk of thrombosis; however, coexistence of MTHFR with other prothrombotic mutations caused an increase in thrombosis risk. 16 This may be an explanation for the lower factor consumption, that is, less frequent bleeding, in patients carrying more than 1 prothrombotic mutation.
Escuriola-Ettingshausen et al 5 reported that the median age at first symptomatic bleeding leading to diagnosis was significantly higher in the carrier group when compared to noncarriers of prothrombotic risk factors (1.6 years vs 0.9 years; P = .01). Considering their findings, we also evaluated the impact of prothrombotic mutations on the age of diagnosis in our patient group. In accordance with our results regarding annual factor consumption, we could not demonstrate any statistically significant difference between carriers and noncarriers of prothrombotic mutations in terms of median age at diagnosis (35 months [range, 1-216] vs 36 months [range, 3-120], respectively; P > .05). However, median age at diagnosis of our patients was clearly higher than that reported in the literature. This may partly be explained by the fact that some of our patients, especially those who lived in suburban areas, had relatively limited access to diagnostic facilities, which resulted in delayed diagnosis.
Twenty of 38 patients (53%) in our study carried inherited prothrombotic risk factors. Heterozygous FVL and factor II mutations were detected in 5 (13%) and 6 (15%) patients, respectively. These numbers are above the reported ranges for a healthy Turkish population. Akar et al 18, 19 reported a frequency of 2.7% for factor II and 9.8% for FVL. Frequency of heterozygosity for MTHFR in a healthy Turkish population was reported to be 28% to 38% in 2 different studies. 17, 20 In our study, 14 patients (36%) carried MTHFR mutation (1 homozygous and 13 heterozygous). The smaller size of the study population and single-center design of the study might have contributed to the relatively higher occurrence rates of prothrombotic mutations in our study.
We did not consider FVIII and FIX gene mutations when evaluating the impact of prothrombotic mutations on clinical severity. This is a limitation of our study given the fact that factor mutation type can directly influence bleeding frequency. On the other hand, the number of patients in our study was too low to stratify them according to their factor genotypes.
In conclusion, we could not demonstrate that presence of prothrombotic risk factors influenced the factor consumption in severe hemophiliacs. This may be a result of the low number of patients in our study. Coinheritance of more than 1 prothrombotic mutation, however, was associated with a milder phenotype and lesser factor consumption. We still think that mechanisms influencing the clinical picture in severe hemophilia are not well established. There is a need for multicenter, large-scale studies conducted in genotypically homogenous groups of severe hemophiliacs to reveal potential modulators of clinical severity.
